Novartis (NVS) has announced a collaboration agreement with the UK-based biotechnology company Relation Therapeutics Ltd., with a potential value of up to $17 billion, aimed at jointly discovering innovative drug targets for the treatment of allergic diseases. Relation will receive an initial funding of $55 million, including upfront payments, equity investments, and research and development funding, and is expected to receive additional rewards based on milestone payments and future sales royalties. Relation’s investors include DCVC and NVentures, the venture capital arm of NVIDIA (NVDA). This collaboration aims to integrate Novartis’s expertise in immunodermatology with Relation’s AI-powered drug discovery platform, which utilizes patient data, including human tissues, to uncover the genetic basis of disease manifestations.
This deal is the latest in a series of proactive transactions by Novartis this year. Previously, the company acquired Avidity Biosciences (RNA) for $12 billion, marking its largest acquisition in over a decade. Additionally, Novartis agreed to acquire Tourmaline Bio for $1.4 billion and Regulus Therapeutics for up to $1.7 billion, while also expanding its cardiology portfolio through the acquisition of Anthos Therapeutics. This series of actions comes against the backdrop of Novartis facing urgent pressure to boost sales after 2025, as several of its key drugs, including the blockbuster heart disease drug Entresto, are set to face competition from cheaper generic alternatives.
Relation focuses on researching atopic diseases—conditions triggered by abnormal immune system responses that affect hundreds of millions of people worldwide. The company’s technology platform is dedicated to accelerating the identification of disease-causing genes and nominating potential targets with higher success rates in drug discovery and development. David Roblin, CEO of Relation, pointed out that up to 75% of drugs entering Phase II clinical trials fail due to efficacy or safety issues, with the root cause often being an insufficient understanding of biology at the initial stages. The collaboration with Novartis began with a chance meeting at the J.P. Morgan Annual Healthcare Conference, and the two parties have spent the past year jointly developing a research plan. Notably, Relation had already entered into a similarly structured agreement with GlaxoSmithKline (GS) in 2024.
J.P. Morgan (JPM) upgraded Novartis from “Neutral” to “Overweight” in its 2026 outlook report, raising the price target from 95 Swiss francs to 125 Swiss francs. The institution predicts that the performance of the pharmaceutical industry will be primarily influenced by the results of pipeline products in the future. It also believes that previous market concerns about potential impacts on industry profits from U.S. drug price pressures largely dissipated in the fourth quarter of last year.
